[go: up one dir, main page]

AU2001257001A1 - Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents - Google Patents

Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents

Info

Publication number
AU2001257001A1
AU2001257001A1 AU2001257001A AU5700101A AU2001257001A1 AU 2001257001 A1 AU2001257001 A1 AU 2001257001A1 AU 2001257001 A AU2001257001 A AU 2001257001A AU 5700101 A AU5700101 A AU 5700101A AU 2001257001 A1 AU2001257001 A1 AU 2001257001A1
Authority
AU
Australia
Prior art keywords
screening methods
antiviral agents
viral proteins
potential antiviral
identifying viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257001A
Inventor
Christopher F. Basler
Adolfo Garcia-Sastre
Peter Palese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of AU2001257001A1 publication Critical patent/AU2001257001A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
AU2001257001A 2000-04-10 2001-04-10 Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents Abandoned AU2001257001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19546500P 2000-04-10 2000-04-10
US60195465 2000-04-10
PCT/US2001/011543 WO2001077394A1 (en) 2000-04-10 2001-04-10 Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents

Publications (1)

Publication Number Publication Date
AU2001257001A1 true AU2001257001A1 (en) 2001-10-23

Family

ID=22721523

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257001A Abandoned AU2001257001A1 (en) 2000-04-10 2001-04-10 Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents

Country Status (3)

Country Link
US (4) US6635416B2 (en)
AU (1) AU2001257001A1 (en)
WO (1) WO2001077394A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4531255B2 (en) 1998-06-12 2010-08-25 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー Attenuated (-) chain virus with modified interferon antagonistic activity for use as a vaccine and medicament
AU2001257001A1 (en) * 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
BRPI0511776B1 (en) 2004-06-01 2016-11-29 Sinai School Medicine genetically engineered swine influenza attenuated virus, immunogenic formulation, pharmaceutical formulation, use of the immunogenic formulation, use of genetically engineered swine influenza attenuated virus, use of the pharmaceutical formulation and method for producing a vaccine, an immunogenic formulation or a pharmaceutical formulation
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8137676B2 (en) * 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
WO2008048276A1 (en) * 2006-10-21 2008-04-24 Arbor Vita Corporation Detection of influenza virus type b
US8066961B2 (en) * 2005-07-20 2011-11-29 Corning Incorporated Kinematic wellplate mounting method
AT502275B8 (en) * 2005-08-08 2007-08-15 Greenhills Biotechnology Res D IMMUNE RESPONSE INDUCING COMPOSITIONS
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
US8258287B2 (en) * 2005-12-21 2012-09-04 Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) Interfering RNAs targeting the morbillivirus nucleoprotein gene
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US8415361B2 (en) * 2007-11-09 2013-04-09 The Salk Institute For Biological Studies Use of TAM receptor inhibitors as antimicrobials
WO2009151697A2 (en) * 2008-03-14 2009-12-17 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and processes relating to human bocavirus
US8083611B2 (en) * 2008-11-05 2011-12-27 Sri Sports Limited Putter-type golf club head
US8480513B2 (en) * 2008-11-05 2013-07-09 Sri Sports Limited Putter-type golf club head
ES2550179T3 (en) * 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Chimeric Newcastle disease viruses and uses thereof
CA2764759A1 (en) * 2009-06-09 2010-12-16 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
JP6178785B2 (en) 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ Cell penetrating anti-DNA antibodies and their use to inhibit DNA repair
WO2013049389A1 (en) 2011-09-27 2013-04-04 Yale University Compositions and methods for transient expression of recombinant rna
US10106817B2 (en) * 2013-02-14 2018-10-23 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
EA038981B1 (en) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Newcastle disease viruses and uses thereof
JP6857498B2 (en) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Combination method for treating cancer
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
WO2016070016A1 (en) 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Compositions and methods for forming emulsions
BR112017015789A2 (en) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh bivalent swine influenza virus vaccine
CN105203477A (en) * 2015-09-15 2015-12-30 天士力金纳生物技术（天津）有限公司 Method for detecting hemagglutinin content of influenza subunit vaccine monovalent stock solution
EP3443077A4 (en) * 2016-04-14 2020-01-01 National University of Singapore FAST PROCESS FOR GENERATING LIVE ATTENUATED VACCINES
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
US11590242B2 (en) 2016-06-15 2023-02-28 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US20190241878A1 (en) 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US20190170737A1 (en) 2016-09-19 2019-06-06 Massachusetts Institute Of Technology Systems including janus droplets
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
KR102777015B1 (en) 2017-08-22 2025-03-10 사나바이오, 엘엘씨 Availability of interferon receptors and their uses
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11053531B2 (en) 2019-05-31 2021-07-06 Linda Marie Petter Tester paper and methods of use thereof for detecting a bacterial infection
WO2021055092A1 (en) 2019-09-18 2021-03-25 Massachusetts Institute Of Technology Systems and methods for affecting interactions of electromagnetic radiation with janus droplets for sensitive detection of species
WO2021258075A2 (en) * 2020-06-18 2021-12-23 Whitehead Institute For Biomedical Research Viral condensates and methods of use thereof
US20240301006A1 (en) * 2020-12-23 2024-09-12 Glaxosmithkline Biologicals Sa Self-amplifying messenger rna
CZ36309U1 (en) 2022-06-22 2022-08-30 OZONTECH, s.r.o. Recycling line for recycling polluted water from rinsing pool filters

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071618A (en) * 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5939831A (en) 1982-08-27 1984-03-05 Biseibutsu Kagaku Kenkyusho:Kk Inactivated influenza virus vaccine for swine
JPS60202827A (en) * 1984-03-28 1985-10-14 Chibaken Attenuated variola vaccine strain
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5786199A (en) * 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5766601A (en) 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
DE570357T1 (en) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptides that induce antibodies that neutralize genetically divergent HIV-1 isolations.
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
DE69532369T3 (en) 1994-07-18 2010-11-04 Conzelmann, Karl-Klaus, Prof. Dr. Recombinant infectious non-segment shared negative-stranded RNA virus
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DK0780475T4 (en) 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Method of producing infectious negative-strand RNA virus
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
JPH11512609A (en) 1995-09-27 1999-11-02 アメリカ合衆国 Production of infectious respiratory syncytial virus from cloned nucleotide sequence
BRPI9710363B8 (en) 1996-07-15 2021-07-06 Us Gov Health & Human Serv attenuated recombinant respiratory syncytial virus (rsv) particle, vaccine to induce protection against recombinant respiratory syncytial virus (rsv), expression vector, and method of producing an infectious recombinant respiratory syncytial virus (rsv).
KR20000048628A (en) 1996-09-27 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
WO1998039487A1 (en) * 1997-03-05 1998-09-11 Ribogene, Inc. Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
BR9809456B1 (en) 1997-05-23 2011-06-28 isolated polynucleotide molecule, cell-free or cell-free composition, infectious, attenuated and immunogenic piv particle, and, immunogenic composition.
EP1012244B1 (en) 1997-07-11 2007-05-09 Yale University Rhabdoviruses with reengineered coats
CN1273603A (en) 1997-09-19 2000-11-15 美国氰胺公司 Attenuated respiratory syncytial viruses
US5853794A (en) * 1997-10-31 1998-12-29 Kemet Electronics Corp. Doped polyaniline solutions
JP4531255B2 (en) 1998-06-12 2010-08-25 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー Attenuated (-) chain virus with modified interferon antagonistic activity for use as a vaccine and medicament
DE69937999T2 (en) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag INTERFERON INDUCING GENETICALLY MODIFIED ATTENUATED VIRUSES
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
EP1259629B1 (en) 2000-03-02 2005-07-20 Polymun Scientific Immunbiologische Forschung GmbH Recombinant influenza a viruses
AU2001257001A1 (en) * 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (en) * 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS proteins antagonize the interferon (IFN) response
EP1358319B1 (en) 2000-09-25 2009-06-17 Polymun Scientific Immunbiologische Forschung GmbH Live influenza vaccine and method of manufacture
US20080234175A1 (en) 2002-11-13 2008-09-25 Montelione Gaetano T Process for Designing Inhibitors of Influenza Virus Structural Protein 1
BRPI0511776B1 (en) 2004-06-01 2016-11-29 Sinai School Medicine genetically engineered swine influenza attenuated virus, immunogenic formulation, pharmaceutical formulation, use of the immunogenic formulation, use of genetically engineered swine influenza attenuated virus, use of the pharmaceutical formulation and method for producing a vaccine, an immunogenic formulation or a pharmaceutical formulation
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
US7507411B2 (en) 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants

Also Published As

Publication number Publication date
US20020090608A1 (en) 2002-07-11
US20060216701A1 (en) 2006-09-28
US20050003343A1 (en) 2005-01-06
US7060430B2 (en) 2006-06-13
US7833774B2 (en) 2010-11-16
WO2001077394A1 (en) 2001-10-18
US20090028901A1 (en) 2009-01-29
US6635416B2 (en) 2003-10-21
US7442527B2 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
AU2001257001A1 (en) Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
AU6700598A (en) Intron-mediated recombinant techniques and reagents
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
IL148300A0 (en) Mammalian cytokines; related reagents and methods
AU4341502A (en) Nod2 nucleic acids and proteins
AU2002321931A1 (en) Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AU1905399A (en) Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
AU2002310502A1 (en) In vitro protein interaction detection systems
AU2222700A (en) Class ii cytokine receptor-like proteins and nucleic acids encoding them
AU3873200A (en) Mammalian cytokines; related reagents and methods
AU2797799A (en) (in vitro) model for viral infection and immune response
EP0747482A3 (en) Hepatitis GB virus recombinant proteins and uses thereof
AU2002368225A1 (en) Viral interferon antagonists and uses therefor
AU2002236066A1 (en) Non-separation assay and system using opaque particles
AU2735002A (en) Nod2 nucleic acids and proteins
AU2377097A (en) Antiviral ricin-like proteins
AU4554899A (en) Novel hepatitis c virus peptides and uses thereof
AU1891301A (en) Novel polypeptide and dna thereof
IL138804A0 (en) Hepatitis c virus ns5b nucleic acids and proteins
SI1121382T1 (en) Interferon-beta fusion proteins and uses
AU1551801A (en) Chemokine slc-il2 fused protein and gene thereof
AU2001283488A1 (en) Methods for classifying nucleic acids and polypeptides
AU6258399A (en) Intron-mediated recombinant techniques and reagents
AU7334498A (en) Hepatitis b virus mutations